Quentin Massé – Theradiag

10/06/2021: Theradiag: report of the extraordinary general meeting on second call of June 10, 2021

Post author:Quentin Massé
Post published:10 June 2021
Post category:Press Releases

Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces that the Extraordinary General Meeting…

31/05/2021: Theradiag announces the launch of HUMABDIAG, a large-scale research project targeting the bioproduction of monoclonal antibodies in Tours

Post author:Quentin Massé
Post published:31 May 2021
Post category:Press Releases

Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces the launch of HUMABDIAG, a large-scale…

10/05/2021: Theradiag announces the adoption of all ordinary resolutions at the Shareholders’ Meeting of May 6, 2021

Post author:Quentin Massé
Post published:10 May 2021
Post category:Press Releases

The Extraordinary Shareholders’ Meeting will be held on June 10, 2021 on the second call Croissy-Beaubourg, May 10, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics…